Trials In Focus: Allogene Off-The-Shelf Study Mirrors Earlier CAR-T Trials
Trial Design Draws Analyst Praise
In Scrip’s new column tracking clinical trial developments, NewAmsterdam, CatalYm, Verve, Bellerophon and Almirall announced new trials or changes to existing ones, while CROs Parexel and PPD announced new programs and CTI appointed a new exec.
You may also be interested in...
R&D head Zachary Roberts spoke with Scrip about Allogene’s Phase II pivotal trial for ALLO-501A and the firm’s hopes for overcoming challenges with allogeneic CAR-T therapies in solid tumors.
Gilead’s Kite is the current leader in CAR-T, but is looking for ways to stay ahead of competitors and find safer and more effective next-generation therapies.
Allogene hopes its off-the-shelf CAR-T can begin a potentially pivotal Phase II study by the end of this year but is frustrated by an “under-resourced and overworked FDA.”